Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, announced that management will participate in two upcoming investor conferences in June.
ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)-- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in two upcoming investor conferences in June:
- Jefferies Healthcare Conference
Format: Presentation
Presentation Date/Time: Wednesday, June 8, 2022 at 4:30 p.m. ET
Location: New York City
- 2022 Truist Securities symposia-cel
Format: Panel titled “Novel Engineered NK Cell Therapies: Pursuit of The Right Phenotype”
Presentation Date/Time: Tuesday, June 28, 2022 at 11:00 a.m. ET
Location: New York City
About Wugen
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies with a cytokine-induced memory-like (CIML) phenotype, uniquely designed to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005026/en/
Contacts
Investor:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com
Source: Wugen, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220601005026/en
